A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Orteronel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Millennium; Takeda Oncology
- 07 Jun 2017 Biomarkers information updated
- 28 Mar 2016 Number of treatment arms changed from 3 to 8 with different doses of Orteronel and Prednisone.
- 31 Mar 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.